You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. A capsule-based bioconjugate vaccine to prevent Klebsiella pneumoniae infections

    SBC: VaxNewMO            Topic: NIAID

    PROJECT SUMMARY Klebsiella pneumoniae is an encapsulated human pathogen capable of causing a myriad of human infections. Recently, K. pneumoniae has also emerged as one the most common causes of secondary bacterial pneumonia in COVID-19 patients. Over the last 40 years, K. pneumoniae has evolved into two distinct pathotypes, known as classical K. pneumoniae (cKp) and hypervirulent K. pneumoniae (h ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  2. Acne Vaccines Targeting a Surface Sialidase and a Secreted CAMP Factor Toxin

    SBC: VAXIN INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Propionibacterium acnes (P. acnes) is most notably recognized for its role in acne vulgaris, the most common skin disease, affecting 85-100% of the population at some point in their lives. Current treatments for vulgari s acne using isotretinoin (13-cis-retinoic acid) or antibiotics can have many undesirable effects, including depression, teratogenicity, hormon ...

    STTR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health
  3. Acute-infarct selective cardiac MRI contrast agent

    SBC: ELGAVISH PARAMAGNETICS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Reliable diagnostic differentiation between acute and chronic myocardial infarcts would be of great benefit for cardiac surgeons and interventional cardiologists. Such differentiation could be used to make decisions about which vessels and in what order would be reopened or bypassed. MRI is an intrinsically noninvasive diagnostic tool and the Delayed Enhancemen ...

    STTR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  4. Acute-infarct selective cardiac MRI contrast agent

    SBC: ELGAVISH PARAMAGNETICS, INC.            Topic: NHLBI

    DESCRIPTION provided by applicant The overall goal of this project is to demonstrate the ability of our acute myocardial infarct selective paramagnetic contrast agent Gadolinium ABE DTTA to differentiate between acute and chronic infarcts in a reliable manner using contrast enhanced magnetic resonance imaging ceMRI In our Phase I data we have shown that Gd ABE DTTA exclusively highlight ...

    STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
  5. A Deep Learning Model to Improve Pathologist Interpretation of Donor Kidney Biopsies

    SBC: NEWVENTUREIQ LLC            Topic: 300

    PROJECT SUMMARY ABSTRACT More people die every year from kidney disease than breast or prostate cancerKidney transplantation is life saving but is limited by a shortage of organ donors and an unacceptably high donor organ discard rateThe decision to use or discard a donor kidney relies heavily on manual quantitation of key microscopic findings by pathologistsA major limitation of this microscopic ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  6. A Deep Learning Model to Improve Pathologist Interpretation of Donor Kidney Biopsies

    SBC: NEWVENTUREIQ LLC            Topic: 400

    ABSTRACT More people die every year from kidney disease than breast or prostate cancer. Kidney transplantation is life-saving, yet the donor organ shortage and high organ discard rate contributes to 13 deaths daily among patients awaiting transplant. The decision to use or discard a donor kidney relies heavily on microscopic quantitation of chronic damage by pathologists. The current standard of c ...

    STTR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  7. A Deep Learning Model to Quantify Arteriosclerosis in Donor Kidney Biopsies

    SBC: NEWVENTUREIQ LLC            Topic: 400

    ABSTRACT More people die every year from kidney disease than breast or prostate cancer. Kidney transplantation is life-saving, yet the donor organ shortage and high organ discard rate contributes to 13 deaths daily among patients awaiting transplant. The decision to use or discard a donor kidney relies heavily on microscopic quantitation of chronic damage by pathologists. The current standard of c ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  8. ADENOVIRUS REPLICATION-COMPETENT ANTI-CANCER VECTOR

    SBC: VIRRX, INC            Topic: N/A

    DESCRIPTION (provided by applicant): We have developed several tumor-specific and tissue-specific replication-competent adenoviruses (Ad) vectors for cancer gene therapy. One vector, named KD3, has a mutation in the E1A gene such that KD3 cannot replicate in, and destroy, "normal" cells. However, KD3 can replicate in cancer cells because they have a microenvironment conducive to KD3 replication. ...

    STTR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health
  9. ADENOVIRUS REPLICATION-COMPETENT ANTI-CANCER VECTOR

    SBC: VIRRX, INC            Topic: N/A

    DESCRIPTION (provided by applicant): We have developed several tumor-specific and tissue-specific replication-competent adenoviruses (Ad) vectors for cancer gene therapy. One vector, named KD3, has a mutation in the E1A gene such that KD3 cannot replicate in, and destroy, "normal" cells. However, KD3 can replicate in cancer cells because they have a microenvironment conducive to KD3 replication. ...

    STTR Phase II 2002 Department of Health and Human ServicesNational Institutes of Health
  10. Adenovirus vectored vaccines for Alzheimer's disease

    SBC: VAXIN INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Alzheimer disease (AD) is the most common neurodegenerative disease in the elderly. To date, no satisfactory treatment is available for AD. One of the pathological hallmarks of AD is deposits of amyloid protein (Aa) in neuritic plaques and cerebral vessels. Increasing lines of evidence support the notion that Aa and its precursor (APP) play pathogenetic roles i ...

    STTR Phase I 2007 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government